Amyotrophic lateral sclerosis therapy extension

Insitro and Bristol Myers Squibb extend their collaboration to use the ChemML platform to turn a preclinical amyotrophic lateral sclerosis (ALS) target into potential medicines. The extension could bring up to $20 million in funding, with milestones and royalties potentially exceeding $2 billion. ChemML uses big data, AI design, and 192 GPUs to speed up discovery of new medicines that could help the disease and extend lives.